Hypothesis

Chronic enhancement of gut‑derived short‑chain fatty acid (SCFA) production through a targeted synbiotic regimen will preserve enteric nervous system (ENS) neuron number and function, thereby increasing vagal afferent tone. This heightened vagal signaling will suppress microglial activation in the brain via dual pathways: (1) SCFA activation of vagal afferent FFAR2 receptors that relay anti‑inflammatory signals to the nucleus tractus solitarius, and (2) direct SCFA mediation of microglial FFAR2/FFAR3 receptors promoting an anti‑inflammatory phenotype. Consequently, age‑related neuroinflammation and cognitive decline will be delayed, and lifespan will be extended.

Mechanistic Rationale

• ENS as a modulator of vagal tone: Enteroendocrine cells release serotonin and peptide YY in response to luminal nutrients; these molecules activate vagal afferents via 5‑HT3 and Y2 receptors, influencing brainstem nuclei that regulate autonomic output. Preserving ENS neuron density (which declines ~50% with age) ensures robust neurochemical signaling to the vagus ENS degeneration.
• SCFA‑vagus coupling: Butyrate and propionate bind FFAR2 on vagal afferents, increasing firing frequency and HRV, an index of vagal tone Vagal activation by probiotics. Enhanced vagal firing releases acetylcholine in the spleen and brain, inhibiting NF‑κB signaling in microglia.
• SCFA‑microglia coupling: SCFAs cross the blood‑brain barrier and engage microglial FFAR2/FFAR3, driving a shift toward an anti‑inflammatory (M2) phenotype characterized by increased Arg1 and IL‑10, reduced iNOS and TNF‑α. This mirrors observations where butyrate supplementation attenuates LPS‑induced microglial activation SCFA microglial effects.
• Feedback loop: Reduced microglial cytokine output lessens sympathetic drive to the gut, limiting further ENS stress—a positive feedback that stabilizes the gut‑brain axis.

Experimental Design (Mouse Model)

1. Groups (n=30 per group, male C57BL/6, start at 12 months):
   • Control diet
   • Control + vagotomy (to test vagal dependence)
   • Synbiotic: Clostridium butyricum (butyrate producer) + Lactobacillus rhamnosus + 5% inulin (fermentable fiber)
   • Synbiotic + FFAR2 antagonist (to dissect receptor role)
2. Intervention duration: 12 months.
3. Readouts (taken at baseline, 6, 12 months):
   • ENS neuron density (HuC/D staining in ileum & colon) ENS degeneration
   • Fecal SCFA concentrations (GC‑MS)
   • Vagal tone: HRV via ECG telemetry
   • Brain microglial state: Iba1/CD68 immunofluorescence, Arg1/iNOS ratio, cytokine panel (IL‑1β, TNF‑α, IL‑10)
   • Blood LPS levels (LAL assay)
   • Cognitive performance: Morris water maze, novel object recognition
   • Survival and frailty index

Predictions & Falsifiability

• If the hypothesis is correct: Synbiotic mice will show (a) ≤15% ENS neuron loss vs. ~45% in controls, (b) ↑HRV (~30% increase), (c) ↓brain microglial activation markers (≥40% reduction), (d) lower systemic LPS, (e) improved spatial memory, and (f) extended median lifespan (~15% increase). Vagotomy or FFAR2 blockade should abolish these benefits, confirming the vagal‑SCFA mediation.
• If the hypothesis is false: No significant differences in ENS preservation, vagal tone, or neuroinflammatory outcomes between synbiotic and control groups, or benefits persist despite vagotomy/FFAR2 antagonism, indicating alternative pathways.

Broader Implications

Validating this bottom‑up model would reposition the ENS as a primary longevity target, suggesting that microbiota‑directed diets or engineered probiotics could be used to pre‑emptively safeguard brain health. It also provides a mechanistic bridge between widely observed correlations of gut dysbiosis, low HRV, and accelerated cognitive aging, offering a testable, intervention‑driven framework for future geroprotective strategies.